Test Price
1,600 AED✅ Home Collection Available
Chronic Neutrophilic Leukemia (CNL) CSF3R & SETBP1 Mutation Analysis in UAE | 1600 AED | DHA Licensed
Executive Summary & Core Metrics
Targeted Sanger sequencing for CSF3R (exons 14, 17) and SETBP1 (exon 4) hotspot driver mutations delivers definitive diagnosis, risk stratification, and targeted kinase inhibitor therapy eligibility for Chronic Neutrophilic Leukemia.
- Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 accredited bi-directional Sanger sequencing.
- Collection Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Post-Test Support: Telephonic clinical guidance for result interpretation provided by a Consultant Medical Genetics.
- Insurance Inquiries: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Chronic Neutrophilic Leukemia (CNL) is a rare BCR-ABL1-negative myeloproliferative neoplasm defined by persistent mature neutrophilia, splenomegaly, and bone marrow hypercellularity. This molecular assay employs gold-standard bi-directional Sanger sequencing to interrogate the canonical activating mutations in CSF3R (exons 14 and 17) and SETBP1 (exon 4). Detection of these mutations confirms the diagnosis, differentiates CNL from reactive neutrophilia and other MPNs, and identifies patients eligible for targeted kinase inhibitor therapy (e.g., ruxolitinib).
| Feature | Our Test (Sanger Sequencing) | Closest Alternative (NGS Panel) |
|---|---|---|
| Precision & Focus | Gold-standard bi-directional Sanger sequencing of CSF3R exons 14,17 & SETBP1 exon 4; >99.9% sensitivity for known mutations | Broad NGS coverage may have lower depth in specific exons; may miss low-level variants |
| Turnaround Time | 7–8 days | 14–21 days |
| Cost (UAE) | 1600 AED | ~2500 AED |
Physician Insight & Safety Protocols
Genetic confirmation of CSF3R and SETBP1 mutations provides a definitive molecular cornerstone for CNL diagnosis. However, correlation with complete blood counts, bone marrow morphology, cytogenetics, and clinical history is indispensable. These mutations, while highly specific, are not universal; a negative result does not entirely exclude CNL if strong clinical suspicion persists. Integrate all laboratory and clinical data to avoid misclassification with atypical CML or other neutrophilic neoplasms. Therapy decisions should be guided by the full hematological picture, not by molecular results alone.
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Advisory Note
Do not discontinue, adjust, or initiate any prescribed therapy including kinase inhibitors, cytoreductive agents, or anticoagulants based solely on these genetic results. All treatment modifications must be made by your managing hematologist-oncologist within the full clinical context.
Exclusion & Safety Criteria
- This test is indicated only when persistent mature neutrophilia (ANC >13×10⁹/L) and clinical suspicion of CNL exist; not for asymptomatic screening.
- Bone marrow aspiration requires platelet count >50×10⁹/L and normal coagulation parameters; contraindicated in patients with severe bleeding diathesis or uncorrected coagulopathy.
- Relative contraindication during pregnancy and lactation; individual maternal-fetal risk-benefit assessment is mandatory before proceeding.
ER Red Flags: Seek immediate urgent care if you experience severe bone pain, uncontrolled bleeding, symptoms of leukostasis (dyspnea, visual disturbances, confusion), or fever with neutropenia following the collection procedure.
Patient FAQ & Clinical Guidance
1. What is the purpose of this CNL mutation test?
This test detects driver mutations in the CSF3R and SETBP1 genes, which are strongly associated with Chronic Neutrophilic Leukemia. A positive result confirms the diagnosis, distinguishes CNL from other myeloproliferative neoplasms, and identifies patients likely to respond to targeted kinase inhibitor therapy such as ruxolitinib.
2. How is the sample collected and what should I expect?
Sample collection is performed exclusively within an accredited hospital setting by a trained hematologist or oncologist. Both bone marrow aspirate and peripheral blood are accepted matrices. Local anesthesia is used for bone marrow aspiration to minimize discomfort. The procedure is safe when pre-procedure coagulation and platelet thresholds are met.
3. When will I receive my results and who will explain them to me?
Results are reported within 7–8 business days from sample receipt at the laboratory. Your Consultant Medical Genetics or hematologist-oncologist will interpret the findings alongside your blood counts, bone marrow histology, and clinical presentation to formulate a comprehensive management plan.
4. Can this test be performed during pregnancy or while breastfeeding?
Bone marrow aspiration and genetic testing carry low direct fetal risk, but the procedure is relatively contraindicated during pregnancy and lactation. An individual risk-benefit assessment involving your obstetrician and hematologist is mandatory. Alternative less invasive diagnostic pathways should be explored first.
5. Is this test covered by my health insurance in the UAE?
Coverage varies by insurer and policy. DNA Labs UAE offers direct billing verification for many UAE health insurance plans. Send your policy details via WhatsApp to +971 54 548 8731 for a real-time coverage and co-pay assessment before the procedure.
UAE Regulatory & Data Privacy Adherence
This genetic testing service is delivered in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic sequence data, clinical records, and personal identifiers are encrypted in transit and at rest, processed within an ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited laboratory environment. Access is restricted on a strict need-to-know basis. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Chronic Neutrophilic Leukemia (CNL) CSF3R & SETBP1 Mutation Analysis |
| Price (AED) | 1600 AED |
| Turnaround Time | 7–8 business days |
| Sample Type / Matrix | Bone marrow aspirate or peripheral blood — Hospital Extraction Only |
| Methodology Used | Bi-directional Sanger Sequencing (CSF3R exons 14, 17; SETBP1 exon 4) |
| ICD-10-CM Code | C92.3 |
| LOINC Code | 94852-7 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians